Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Celiac Clear all
Withdrawn Not applicable Interventional

Endoscopic Ultrasound-guided Celiac Plexus Neurolysis in the Management of Pain in Abdominal Non-pancreatic Malignancies

NCT01166529
View directory record Official record
Conditions
Pain, Cancer
Interventions
EUS-guided Celiac Plexus Neurolysis
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 22, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

NCT04530123
View directory record Official record
Conditions
Celiac Disease
Interventions
Placebo, TAK-101, Gluten
Drug · Dietary Supplement
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Escondido, California • Poway, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 8:14 AM EDT
Completed No phase listed Observational

A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease

NCT03521180
View directory record Official record
Conditions
Celiac Disease
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Jul 22, 2026, 8:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Immune Responses to Gluten

NCT05209568
View directory record Official record
Conditions
Celiac Disease, Malabsorption Syndromes, Digestive System Disease, Intestinal Disease, Gastrointestinal Diseases, Gluten Sensitivity, Celiac Disease in Children
Interventions
Gluten Powder
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 101 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Jul 22, 2026, 8:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Online Health Tool About Down Syndrome: Down Syndrome Clinic to You

NCT04227197
View directory record Official record
Conditions
Down Syndrome
Interventions
Down Syndrome Clinic to You (DSC2U)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year and older
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jul 22, 2026, 8:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Urine Metabolites in the Diagnosis of Disease

NCT06710067
View directory record Official record
Conditions
Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
Interventions
Not listed
Lead sponsor
Luventix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Encinitas, California • Santa Monica, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 22, 2026, 8:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gluten-Free Diet in Patients With Gluten Sensitivity and Cerebellar Ataxia

NCT00006492
View directory record Official record
Conditions
Celiac Disease, Cerebellar Ataxia, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 8:14 AM EDT
Completed No phase listed Observational

Intracellular Tight Junction Permeability in Schizophrenia: Focus on Zonulin

NCT01558570
View directory record Official record
Conditions
Schizophrenia, Celiac Disease
Interventions
Blood Draw
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Jul 22, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

NCT02633020
View directory record Official record
Conditions
Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
Interventions
AMG 714, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Jul 22, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

NCT03738475
View directory record Official record
Conditions
Celiac Disease
Interventions
TIMP-GLIA, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Jacksonville, Florida • Meridian, Idaho • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jul 22, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients

NCT02389062
View directory record Official record
Conditions
Adult Form of Celiac Disease
Interventions
Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Jul 22, 2026, 8:14 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule

NCT02202681
View directory record Official record
Conditions
Celiac Disease, Healthy
Interventions
OFDI Capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 22, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

NCT06001177
View directory record Official record
Conditions
Celiac Disease, Coeliac Disease
Interventions
KAN-101, Placebo
Drug
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Colorado Springs, Colorado • Hialeah Gardens, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 22, 2026, 8:14 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

NCT03569007
View directory record Official record
Conditions
Celiac Disease
Interventions
Larazotide, Matching Placebo
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
160
States / cities
Saraland, Alabama • Scottsdale, Arizona • Tucson, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 22, 2026, 8:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gut Permeability Assessment in Celiac and Gluten Sensitive Children

NCT02690532
View directory record Official record
Conditions
Celiac Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jul 22, 2026, 8:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 22, 2026, 8:14 AM EDT
Completed No phase listed Observational

A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)

NCT05686369
View directory record Official record
Conditions
Celiac Disease
Interventions
Not listed
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Jul 22, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Evaluation of Injection Techniques in Celiac Plexus Neurolysis

NCT02068677
View directory record Official record
Conditions
Pancreatic Cancer, Pain
Interventions
Sympathetic response, no sympathetic response
Other
Lead sponsor
AdventHealth
Other
Eligibility
19 Years to 89 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 22, 2026, 8:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictive Genetic Risk Assessment Trial

NCT00782366
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
Interventions
SNP analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Jul 22, 2026, 8:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

NCT04477928
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Sera and whole blood sampling, Differential Gene Expression (DGE)
Diagnostic Test
Lead sponsor
Sanford Health
Other
Eligibility
0 Minutes to 17 Years
Enrollment
33,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2031
U.S. locations
4
States / cities
Bemidji, Minnesota • Bismarck, North Dakota • Fargo, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 22, 2026, 8:14 AM EDT
Recruiting Phase 1 Interventional

A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

NCT07377565
View directory record Official record
Conditions
Celiac Disease
Interventions
HB-2121
Drug
Lead sponsor
Nielsen Fernandez-Becker
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 8:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gluten Ingestion Biomarkers in Patients w Gluten Sensitivity and Healthy Controls Peptides in Patients With Non-celiac Gluten Sensitivity and Healthy Patients: A Placebo-controlled Study

NCT02936297
View directory record Official record
Conditions
Non Celiac Gluten Sensitivity
Interventions
High dose Gluten, Low dose Gluten, Lactose free placebo
Dietary Supplement
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jul 22, 2026, 8:14 AM EDT
Completed Phase 1 Interventional Results available

Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

NCT03486990
View directory record Official record
Conditions
Celiac Disease
Interventions
TIMP-GLIA
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Jul 22, 2026, 8:14 AM EDT
Terminated Phase 4 Interventional Results available

Budesonide in Patients With Immune Mediated Enteropathies

NCT03866538
View directory record Official record
Conditions
Enteropathy, Celiac Disease, CVID Enteropathy, Collagenous Sprue, Autoimmune Enteropathy
Interventions
Withdrawal of Oral Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jul 22, 2026, 8:14 AM EDT